Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers